LncRNA HOTAIR: A Potential Prognostic Factor and Therapeutic Target in Human Cancers

Long non-coding RNAs (lncRNAs) are emerging as crucial regulators of gene expression and physiological processes. LncRNAs are a class of ncRNAs of 200 nucleotides in length. HOX transcript antisense RNA (HOTAIR), a trans-acting lncRNA with regulatory function on transcription, can repress gene expre...

Full description

Bibliographic Details
Main Authors: Xiaoru Xin, Qianan Li, Jinyong Fang, Tiejun Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.679244/full
_version_ 1818668810645798912
author Xiaoru Xin
Qianan Li
Jinyong Fang
Tiejun Zhao
author_facet Xiaoru Xin
Qianan Li
Jinyong Fang
Tiejun Zhao
author_sort Xiaoru Xin
collection DOAJ
description Long non-coding RNAs (lncRNAs) are emerging as crucial regulators of gene expression and physiological processes. LncRNAs are a class of ncRNAs of 200 nucleotides in length. HOX transcript antisense RNA (HOTAIR), a trans-acting lncRNA with regulatory function on transcription, can repress gene expression by recruiting chromatin modifiers. HOTAIR is an oncogenic lncRNA, and numerous studies have determined that HOTAIR is highly upregulated in a wide variety of human cancers. In this review, we briefly summarize the impact of lncRNA HOTAIR expression and functions on different human solid tumors, and emphasize the potential of HOTAIR on tumor prognosis and therapy. Here, we review the recent studies that highlight the prognostic potential of HOTAIR in drug resistance and survival, and the progress of therapies developed to target HOTAIR to date. Furthermore, targeting HOTAIR results in the suppression of HOTAIR expression or function. Thus, HOTAIR knockdown exhibits great therapeutic potential in various cancers, indicating that targeting lncRNA HOTAIR may serve as a promising strategy for cancer therapy. We also propose that preclinical studies involving HOTAIR are required to provide a better understanding of the exact molecular mechanisms underlying the dysregulation of its expression and function in different human cancers and to explore effective methods of targeting HOTAIR and engineering efficient and targeted drug delivery methods in vivo.
first_indexed 2024-12-17T06:42:14Z
format Article
id doaj.art-faeaaf6064f84ef09d5b197b05d3162b
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-12-17T06:42:14Z
publishDate 2021-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-faeaaf6064f84ef09d5b197b05d3162b2022-12-21T21:59:50ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-07-011110.3389/fonc.2021.679244679244LncRNA HOTAIR: A Potential Prognostic Factor and Therapeutic Target in Human CancersXiaoru Xin0Qianan Li1Jinyong Fang2Tiejun Zhao3College of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua, ChinaCollege of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua, ChinaDepartment of Science and Education, Jinhua Guangfu Oncology Hospital, Jinhua, ChinaCollege of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua, ChinaLong non-coding RNAs (lncRNAs) are emerging as crucial regulators of gene expression and physiological processes. LncRNAs are a class of ncRNAs of 200 nucleotides in length. HOX transcript antisense RNA (HOTAIR), a trans-acting lncRNA with regulatory function on transcription, can repress gene expression by recruiting chromatin modifiers. HOTAIR is an oncogenic lncRNA, and numerous studies have determined that HOTAIR is highly upregulated in a wide variety of human cancers. In this review, we briefly summarize the impact of lncRNA HOTAIR expression and functions on different human solid tumors, and emphasize the potential of HOTAIR on tumor prognosis and therapy. Here, we review the recent studies that highlight the prognostic potential of HOTAIR in drug resistance and survival, and the progress of therapies developed to target HOTAIR to date. Furthermore, targeting HOTAIR results in the suppression of HOTAIR expression or function. Thus, HOTAIR knockdown exhibits great therapeutic potential in various cancers, indicating that targeting lncRNA HOTAIR may serve as a promising strategy for cancer therapy. We also propose that preclinical studies involving HOTAIR are required to provide a better understanding of the exact molecular mechanisms underlying the dysregulation of its expression and function in different human cancers and to explore effective methods of targeting HOTAIR and engineering efficient and targeted drug delivery methods in vivo.https://www.frontiersin.org/articles/10.3389/fonc.2021.679244/fullHOTAIRcancerprognosistherapypotentialdrug resistance
spellingShingle Xiaoru Xin
Qianan Li
Jinyong Fang
Tiejun Zhao
LncRNA HOTAIR: A Potential Prognostic Factor and Therapeutic Target in Human Cancers
Frontiers in Oncology
HOTAIR
cancer
prognosis
therapy
potential
drug resistance
title LncRNA HOTAIR: A Potential Prognostic Factor and Therapeutic Target in Human Cancers
title_full LncRNA HOTAIR: A Potential Prognostic Factor and Therapeutic Target in Human Cancers
title_fullStr LncRNA HOTAIR: A Potential Prognostic Factor and Therapeutic Target in Human Cancers
title_full_unstemmed LncRNA HOTAIR: A Potential Prognostic Factor and Therapeutic Target in Human Cancers
title_short LncRNA HOTAIR: A Potential Prognostic Factor and Therapeutic Target in Human Cancers
title_sort lncrna hotair a potential prognostic factor and therapeutic target in human cancers
topic HOTAIR
cancer
prognosis
therapy
potential
drug resistance
url https://www.frontiersin.org/articles/10.3389/fonc.2021.679244/full
work_keys_str_mv AT xiaoruxin lncrnahotairapotentialprognosticfactorandtherapeutictargetinhumancancers
AT qiananli lncrnahotairapotentialprognosticfactorandtherapeutictargetinhumancancers
AT jinyongfang lncrnahotairapotentialprognosticfactorandtherapeutictargetinhumancancers
AT tiejunzhao lncrnahotairapotentialprognosticfactorandtherapeutictargetinhumancancers